CLINICAL_TRIALS
trial_result
· 2021-08-16
Clinical Trial Update: Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma [Phase 2]
Summary
Phase 2 trial of oral LBH589 (panobinostat) in adults with refractory cutaneous T-cell lymphoma completed; results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Cutaneous T-Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2021-08-16